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A practical method for the synthesis of peptoids
containing both lysine-type and arginine-type
monomers†
H. L. Bolt and S. L. Cobb*
Peptoids are a promising class of peptidomimetics that exhibit the
key chemical and physical properties of peptides but without
being hampered by susceptibility towards enzymatic degradation.
Biologically active peptoids are often designed to be amphipathic
in nature, consisting of hydrophobic monomers interspersed with
either cationic lysine-type or arginine-type monomers. Access to
amphipathic peptoids that contain both lysine-type and arginine-
type monomers is highly desirable as it oﬀers a route to further
modulate the biological properties of this class of molecule.
However, the lack of a suitable synthetic route to prepare mixed
cationic peptoids has meant that their biological potential has
remained almost largely unexplored. Herein, we present an
eﬃcient synthetic route that can be used to access novel cationic
peptoids containing both lysine-type and arginine-type monomers
within the same sequence.
Peptoids are peptidomimetic molecules that comprise of
repeating poly-N-substituted glycine units.1 In terms of struc-
ture, peptoids diﬀer from peptides in that their side-chain
functionality is bonded to the nitrogen of the poly-amide back-
bone, rather than the α-carbon (Fig. 1a). This repeating N-alkyl
amide backbone motif aﬀords peptoids with an increased
stability towards proteolytic degradation compared to analo-
gous peptides.2 Peptoids can be easily accessed in a cost-
eﬀective and flexible manner via the eﬃcient solid phase sub-
monomer synthesis approach.1 Despite a lack of hydrogen-
bond donor capacity in the peptoid backbone (i.e. no free NH
groups) stable secondary structures such as peptoid helices
can be designed and prepared.3–5 All of the aforementioned
points have meant that peptoids are increasingly being investi-
gated in the field of medicinal chemistry as a realistic option
to replace peptides in the hunt for new therapeutics.6,7
Given the urgent need for the development of new anti-
microbial treatments, both linear and cyclic peptoids are being
increasingly investigated as anti-infective agents. They have
been shown to have promising activity against a variety of
microbial targets including both Gram-positive and Gram-
negative bacteria,8a parasites,8b and fungi.8c In many cases, the
anti-infective activity of peptoids has been found to be compar-
able to leading antimicrobial peptides (AMPs).7 Typically, anti-
microbial peptoids have been designed to mimic simple,
naturally occurring AMPs, and they contain amphipathic struc-
tures (i.e. mixture of hydrophobic and cationic residues). The
presence of cationic side chains within the peptoid sequence
helps to provide a degree of selectivity between zwitterionic
mammalian cell membranes and the more negatively charged
prokaryotic cell membranes. The cationic side chains in pep-
toids come from either the incorporation of lysine- or arginine-
type monomers into the sequence (Fig. 1b). There are numer-
ous examples within the literature of cationic anti-infective
peptoids that contain either lysine-type or arginine-type
monomers.8
Beyond anti-infective applications, amphipathic cationic
peptoids have been studied in other areas of medicinal chemi-
stry. For example, peptoids rich in arginine-type monomers
have been shown to have applications as molecular transpor-
Fig. 1 (a) A comparison of generic α-peptoid and peptide oligomers;
(b) representation of the amino functionalised lysine-type monomers
and guanido functionalised arginine-type monomers, where n = 1–6.
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ters, cell-penetrating vehicles,9–13 heparin binding agents,14
and as analogues of Lung Surfactant Protein B.15
The diﬀerences between the inclusion of lysine-type and
arginine-type side chains for cellular uptake has also been
investigated by several groups and it was shown that guanidine
containing peptoids can translocate into the cell more quickly
than their amino analogues.13 Additionally, it has been
reported that sequences including arginine-type monomers
may have an increased biological activity, however this is typi-
cally accompanied by an increased toxicity towards mamma-
lian cells.16 The aforementioned point highlights that it would
be advantageous to study peptoids that contain mixtures of
lysine- or arginine-type monomers in an eﬀort to fine tune the
balance between toxicity and activity. However, with the excep-
tion of one example,15 all of the peptoids investigated to date
have sequences consisting exclusively of either the lysine-
type (amino functionalised) or exclusively all arginine-type
(guanido functionalised) monomers.
Polyarginine-type peptoids reported in the literature have
generally been made using the method developed by Rothbard
and co-workers.13 This approach uses pyrazole-1-carboxamide
to transform lysine-type monomers into their arginine-type
analogs (i.e. an amino to guanido transformation). This reac-
tion can only be carried out after the peptoid has been cleaved
from the resin and Boc protecting groups removed. Therefore,
every lysine-type residue with the peptoid chain is transformed
into an arginine-type residue and thus it is not possible to use
this approach to synthesise sequences containing both amino
and guanido functionalities.13
The Zuckermann group has previously described the syn-
thesis of a PMC (2,2,5,7,8-pentamethylchroman-6-sulphonyl)
protected guanidinopropyl amine monomer.17 Barron et al.,
attempted to utilise this type of PMC protected monomer in
the on resin synthesis of a mixed guanido/amino linear
peptoid.15 However, poor solubility (of the monomer) led to
low coupling eﬃciency and the extended cleavage times
necessary for the PMC group caused acid-induced degradation
of the mixed peptoid (in particular, deterioration of the com-
monly used Nspe monomer). This prevented full isolation and
purification of the required target mixed arginine/lysine-type
peptoids.
Thus to the best of our knowledge an eﬃcient generally
applicable method for the synthesis of mixed arginine/lysine-
type peptoids is yet to be reported (although peptoid–peptide
hybrids have been made using the amino acids lysine and
arginine).18,19 We were interested in combining arginine- and
lysine-type monomer residues within the same peptoid so that
we could begin to probe their biological activities, and, in
particular the relationship between antimicrobial properties
and cytotoxicity. Herein, we describe the development of an
eﬃcient synthetic approach that can be utilised to synthesise
novel peptoids (linear and cyclic) containing both lysine-type
and arginine-type monomers within the same sequence.
Guanidinylation using pyrazole-1-carboxamide was optimised
and orthogonal Dde protection developed to facilitate this
reaction on resin. This approach benefits from being compati-
ble with the sub-monomer solid-phase synthesis of peptoids,
which is utilised by the majority of the scientific community.
Both linear and cyclic peptoids have been synthesised to show
the versatility and synthetic utility of the methodology
developed.
Results and discussion
Currently, arginine-type monomers can be added to peptoid
sequences using a post-synthetic modification of unprotected
amino moieties. However, this transforms all amino function-
alities, so mixed amino/guanido functionalised peptoids are
not possible via this method. This procedure uses pyrazole-1-
carboxamide, a convenient reagent for the guanidinylation of
simple primary amines that leaves secondary amines
unaﬀected, even when used in large excess.20
In order to incorporate both amino and guanido functiona-
lised side chains (lysine-type and arginine-type monomer resi-
dues respectively) within the same sequence, orthogonal
protection is necessary. Commonly N-Boc protected amines
are used in peptoid synthesis for the protection of amino
groups, for example N-Boc 1,4-diaminobutane. For the other
protecting group, Dde (N-(1-(4,4-dimethyl-2,6-dioxocyclohexyl-
idene)ethyl) was chosen.
Dde is commonly used to protect free primary amines in
peptide synthesis and provides orthogonal protection to the
acid cleavable N-Boc group.21,22 The Dde group is removed
using 2% hydrazine in DMF which allows these residues to be
selectively deprotected (leaving the Boc protection on the other
lysine-type monomers intact). Following complete synthesis of
the peptoid using the sub-monomer method, selective de-
protection of the Dde amine on-resin enables the guanidinyl-
ation reaction at specific positions using pyrazole-1-
carboxamide. Finally, cleavage from the resin under acidic con-
ditions simultaneously deprotects the remaining Boc protected
amino chains to yield a mixed peptoid, containing both lysine-
type and arginine-type peptoid residues (see Fig. 2, steps (iv)
to (vi)).
A variety of mono-N-Boc protected amines are available to
purchase from commercial sources, or can be made in high
dilution syntheses using Boc anhydride and the required
diamine.23 Initially, it was planned to synthesise a mono Dde-
protected amine in a similar manner so it could be used
directly in the sub-monomer procedure. However, in our
hands, the major product of the reaction was a doubly pro-
tected amine under all reaction conditions investigated. There-
fore, this procedure was deemed to be ineﬃcient and an
alternative route to mixed arginine/lysine peptoids was develo-
ped. Instead, the Dde protecting group was added to the free
amine on resin using Dde-OH (2-acetyldimedone). A standard
coupling was made during the displacement stage of the sub-
monomer method with an unprotected diamine and one extra
step added to protect the free amine using Dde-OH. This is
shown in Fig. 2, steps (i) to (iii).
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Adding the Dde group on resin has been used in peptide
synthesis, but has never been used to make mixed arginine-
and lysine-type peptoid residues as far as we are aware.21,22
Addition of Dde-OH (10 eq. wrt resin, in the minimum volume
of DMF necessary to dissolve reagent fully) to the free amine
on resin was complete after 60 minutes at room temperature.
The sub-monomer procedure could then be resumed to
lengthen the peptoid chain successfully. To illustrate all steps
in this process, mass spectra from the syntheses have been
shown in the ESI.†
The guanidinylation reaction with pyrazole-1-carboxamide
as reported by Rothbard et al. must be carried out on fully
deprotected peptoids in solution.13 Additionally, water was
used as a solvent with sodium bicarbonate as a base. Our pro-
cedure uses reaction conditions (e.g. DMF with DIPEA) which
are compatible with solid-phase synthesis. Carrying out the
guanidinylation reaction on resin is preferable as the excess
reagents used can simply be washed away at the end of the syn-
thesis making the final purification easier. In addition,
although not reported here, the methodology developed
should be compatible with automated peptoid synthesisers as
it adds only one step to the commonly used sub-monomer
method and the Dde group is easily introduced under room
temperature conditions.
To demonstrate the versatility of the methodology, a small
library of linear peptoids containing both amino and guanido
moieties within the same sequence were synthesised (see
Table 1). Initially, ‘mixed’ lysine/arginine-type peptoids
Fig. 2 The method used to synthesise mixed arginine/lysine peptoids, where x and y = 1–5; (i) standard displacement step in the sub-monomer
method with diamine, 1.5 M in DMF, 60 minutes, RT; (ii) addition of Dde-OH, 10 eq. wrt resin in minimum volume DMF, 60 minutes at RT to protect
free amine; (iii) further additions to extend the peptoid chain, using the normal sub-monomer procedure; (iv) deprotection of Dde using 2% hydra-
zine in DMF 4 × 3 min; (v) guanidinylation of free amine, on resin, using 6 eq. pyrazole-1-carboxamide per free amine and 6 eq. DIPEA per free
amine in the minimum volume DMF, 60 minutes, RT; (vi) acidic cleavage from the resin and deprotection of Boc groups.
Table 1 Sequences of the all arginine-type and the mixed lysine- /argi-
nine-type peptoids prepared in this study. Peptoids 1–6 are mixed pep-
toids, peptoids 7–10 are arginine-only sequences
Peptoid Sequence
1 (NLysNspeNspe)2(NhArgNspeNspe)2
2 (NhArgNspeNspe)2(NLysNspeNspe)2
3 (NLysNspeNspe)(NhArgNspeNspe)(NLysNspeNspe)2
4 [(NhArgNspeNspe)(NLysNspeNspe)]2
5 [(NnArgNspeNspe)(NLysNspeNspe)]2
6 Cyclic (NLysNpheNhArgNpheNLysNphe)
7 (NhArgNspeNspe)4
8 (NhArgNmfbNmfb)4
9 [(NamyNspeNspe)(NhArgNspeNspe)]2
10 (NnArgNspeNspe)4
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(Table 1, 1–4, 6) were prepared with monomers containing 4
carbons in the side chain (i.e. NLys and NhArg monomers
derived from 1,4-diaminobutane). The Dde group was
introduced at a variety of positions within the sequence. It was
found that the Dde protection reaction on resin was
eﬃcient, it could be carried out near the resin linker at the
C terminus and other Dde-protected residues in the same
sequence were tolerated. The synthesis was also carried out
using the shorter, 2 carbon amine monomer (Nae, Table 1, 5)
to highlight that the methodology works with side chains
of varying lengths (i.e. Nae and NnArg, derived from 1,2-
diaminoethane).
Four all arginine-type peptoids were also synthesised on
resin using the Dde protection strategy developed (Table 1,
7–10). Carrying out the guanidinylation reaction on resin sig-
nificantly simplified the final purification of these peptoids.
The preparation of 7–10 illustrated that the Dde methodology
is compatible not just with Nphe and Nspe but also with other
commonly used amine monomers (i.e. Nmfb and Namy).
A cyclic peptoid (6) with both lysine- and arginine-type resi-
dues was also synthesised via a Dde-protected linear precursor
(Fig. 3). The linear peptoid bearing the Dde-group was success-
fully cleaved from the resin and cyclised in solution. Sub-
sequent Dde-deprotection of the resultant cyclic peptoid
allowed guanidinylation, prior to a final acidic deprotection of
remaining Boc-protected amines. Despite the bulky nature of
the Dde group, the cyclisation still occurred eﬃciently at room
temperature.
Conclusions
We have developed a practical synthetic procedure that can be
used to access linear and cyclic peptoids that contain both
arginine- and lysine-type residues within the same sequence.
This has enabled the preparation of peptoids (Table 1) that
contain combinations of monomers not previously reported in
the literature. The methodology developed utilises orthogonal
N-Boc and N-Dde protection and pyrazole-1-carboxamide as a
guanidinylation reagent. Significantly, this process is amen-
able for use with acid sensitive monomers (i.e. Nspe) and it is
compatible with the commonly used sub-monomer method of
peptoid synthesis. The synthesis of an extended library of
mixed lysine/arginine type peptoids is now underway and the
biological evaluation of these novel compounds will be
reported in due course.
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